News Conference News HFSA 2024 ‘Global Efficacy’ of Aficamten for Obstructive Disease Shown in SEQUOIA-HCM L.A. McKeown October 02, 2024
News Daily News New HCM Guidelines Focus on Cardiac Myosin Inhibitors and Exercise Yael L. Maxwell May 08, 2024
News Conference News ACC 2024 IMPROVE-HCM: Ninerafaxstat May Fill a Niche in Nonobstructive HCM Caitlin E. Cox April 15, 2024
News Conference News ACC 2023 Studies Support (Careful) Return to Sport for Athletes With Genetic Conditions Michael O'Riordan March 07, 2023
News Conference News HFSA 2022 REDWOOD-HCM OLE: Aficamten Improves Patient-Measured Health Status L.A. McKeown October 07, 2022
News Conference News ACC 2022 Mavacamten Yields Stable Benefits in Obstructive HCM Over Longer Term Shelley Wood April 03, 2022
News Conference News STS 2022 Tricuspid Repair During Mitral Valve Surgery Prevents TR Progression Michael O'Riordan February 04, 2022
News Conference News STS 2022 Modified Surgical MV Repair Stands Up to Replacement Michael O'Riordan February 03, 2022
News Conference News ACC 2021 ‘Enormous’ QoL Improvements With Mavacamten in HCM Shelley Wood May 15, 2021
News Daily News AHA’s 2020 Top 10: ISCHEMIA, HCM, Early A-fib Intervention, and More Shelley Wood December 17, 2020
News Conference News ESC 2020 EXPLORER-HCM: Mavacamten Improves Exercise Capacity and Functional Class Michael O'Riordan August 29, 2020
News Conference News HRS 2020 Subcutaneous ICD Holds Up Well Against Transvenous Devices Todd Neale May 13, 2020
News Daily News Mavacamten Successful in Obstructive Hypertrophic Cardiomyopathy: EXPLORER-HCM Shelley Wood May 11, 2020
News Conference News HRS 2019 Cancer Survivors With Heart Failure Respond Well to CRT Todd Neale May 14, 2019